REGENXBIO Inc. (RGNX) stock forecast and price target
Price $7.64 · data as of November 13, 2026
12-month price target
Average target$21.40
Upside / downside+180.1%
Analysts10
ConsensusStrong buy
Low $12.00Average $21.40High $42.00
Gold marker: average target · white marker: today’s price ($7.64)
Analyst ratings
Strong buy 3Buy 7Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.58 | +4.9% | $160M |
| Next fiscal year ends December 31, 2027 | $-3.28 | +8.2% | $198M |
| Next quarter ends December 31, 2026 | $-1.49 | −14.4% | $9M |
| Quarter after ends March 31, 2027 | $-0.99 | +42.4% | $9M |
Consensus of the analysts covering REGENXBIO, updated daily. In the last 30 days 2 estimates were raised and 1 lowered.
Frequently asked questions
What is the REGENXBIO stock price target?
The average 12-month target from 10 analysts is $21.40, 180.1% above the current price of $7.64 Targets range from $12.00 to $42.00.
Is REGENXBIO a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 7 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is REGENXBIO expected to earn?
Analysts expect EPS of $-3.58 for the fiscal year ending December 31, 2026 and $-3.28 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.